Statement by Mr. François Hollande, President of the Republic, on INSERM and French medical research, in Paris on April 3, 2014.

France François Hollande · President of France

3 April 2014 · INSERM 50th anniversary · Paris, France

Context
Hollande addressed a ceremony marking the 50th anniversary of INSERM, France's national institute for health and medical research, in Paris on April 3, 2014.
Main themes
INSERM anniversary, French medical research, biomedical innovation, fundamental research, molecular medicine, genomics and DNA decoding, Nobel Prize laureates, hospital-university reform, public investment in science, research pioneers, predictive medicine
Duration
~24 min
73rd percentile
Words
2,857
73rd percentile
Sentences
172
85th percentile
Readability
49
60th percentile
Grade
10.4
25th percentile
Syntax
2.77
19th percentile
Vocabulary
2.09
25th percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 31%28%
  • Institutional 25%23%
  • Economic 21%20%
  • Ceremonial 15%14%
  • Technological 4%4%
  • Geopolitical 4%3%
  • Environmental 0%0%
  • Not in focus 8%

172 sentences in 48 paragraphs

Madam European Commissioner,

It is through your presence that you symbolize Europe's recognition of the work of French research,

Ladies and gentlemen ministers,

Ladies and gentlemen parliamentarians,

Ladies and gentlemen researchers,

And especially you, Mr. President, Director General of INSERM,

Fifty years ago, your institution was founded. For an institution, 50 years, as you reminded us, is very young since you have had particularly famous ancestors. There was already in 1964 an institute that bore the name National Institute of Hygiene. This did not necessarily reveal the ambition of research. So General de GAULLE decided to create the National Institute of Health and Medical Research. A simple decree, signed in the summer of 1964, surely in general indifference, would nevertheless disrupt the organization of medical research.

I draw a conclusion from this. It is possible to make a revolution by decree. This makes those who sign them even more responsible for what is done or not done, and ministers even more modest... Why make a law when a simple decree is enough? Why make laws all year round when in July, and why not in August? we can change the game? That is what happened 50 years ago.

Today, INSERM has 15,000 collaborators, boasts 300 laboratories, heads a budget of almost 1 billion euros—I rounded it to leave you with hope—and is responsible for nearly 10,000 scientific publications each year. This is a considerable result.

INSERM did not come from nowhere. It did not achieve its results simply through the mobilization of public authorities or the encouragement of a budget. This institute first had to have personalities at its head; I salute here all the directors who have succeeded one another and others who have been pioneers in their field.

I am thinking in particular of:

- Louis BUGNARD, who long ago enabled generations of students, particularly medical students, to train in the United States. This is commonplace today. It was a considerable initiative at the time and almost a scandalous factor! How to send our best students to the United States with the risk that they might stay there? Undoubtedly some may have made that choice. Most returned. One must always take the gamble of adventure, of shared experience, and thus of openness.

- Another great personality, Robert DEBRE. He was the originator of the hospital-university reform which, even if it has evolved, has retained research and medicine at its core.

- And then all these great professors, Jean HAMBURGER, Jean BERNARD, Georges MATHE, who also worked to bring as much medical research as possible into the hospital.

In their wake, INSERM has been able to develop cutting-edge research crowned by a first Nobel Prize in 1980, awarded to Jean DAUSSET, and then in 2008 by a second, awarded to Françoise BARRE-SINOUSSI, co-discoverer of the HIV retrovirus with Luc MONTAGNIER and Jean-Claude CHERMANN. I salute her because she is still present at events for research when the essential is at stake.

Beyond these personalities, beyond these distinctions, beyond these doctors who have devoted themselves to making INSERM what it is today, I would like to salute, as you have done, Mr. President Director General, the researchers, technicians, and administrative staff of this institute who together push the boundaries of knowledge about life. Many come from abroad because you have gained a worldwide reputation. You have made French biomedical research shine in all universities and laboratories.

You said it, Mr. President, research, fundamental research, is a long-term endeavor. It is to promise advances that may never happen and, if they do happen, will only appear in ten or twenty years. Fundamental research is to accept failure but it is also to imagine the unexpected. No one can anticipate what fundamental research will yield. That is why it must be encouraged and supported. But when success is there, when the discovery is made, then it is a breakthrough.

The most spectacular example, you provided, is molecular medicine. This medicine of the infinitely small where diagnosis and treatment are done at the level of proteins. When Georges SCHAPIRA created the Institute of Molecular Pathology at Cochin in 1968, he had the intuition of the meeting between clinical research and the new life sciences. From this meeting, a new medicine would be born. It has happened. This new medicine is the medicine of today.

And then, there was the increase in computing power of computers that allowed you to decipher the mysteries of DNA. The decoding of the genome now allows us to understand many diseases, to explain their causes, and even to ensure their treatments. I want to salute INSERM here for having achieved the first complete sequencing of the Hepatitis B virus genome as early as 1979, paving the way for the first human vaccine against this disease.

Genetics thus fosters the emergence of this predictive medicine that prevents diseases and can even sometimes prevent them from appearing. It is a new way of conceiving treatments. The third Cancer Plan that I announced a few weeks ago precisely chooses genetics as one of its greatest priorities. It should enable the advent of personalized medicine where treatments will be adapted to each tumor and each patient.

But there is not just genetics. There are also the parallel advances in biochemistry and medical imaging that have, it is true, opened up an infinite field of research in neuroscience. Researchers are deciphering the mechanisms of brain function and hope that soon we will be able to better treat neurodegenerative diseases and better repair injuries to the spinal cord and brain. Here too, great progress has been made thanks to you.

Finally, the last illustration is the epidemic risk that was thought to be gone and which resurfaces with globalization, with the movement of people. Infectious agents follow people. Thus, there was first AIDS. But now we have other alerts: prion diseases, chikungunya, flu, coronaviruses, and today even Ebola fever.

I was in Brussels yesterday for a meeting between the European Union and the African Union. We talked about everything as often, that is to say, security, peace for the African continent, development, the issue of climate. But current events eventually resurfaced. From Guinea indeed comes the risk of a new epidemic. It is not simply a matter of showing solidarity and generosity towards a country affected by this disease, but simply of protecting ourselves.

I proposed for the African Union and the European Union an alliance, a true alliance: an alliance for peace and against terrorism, surely an alliance for development and to protect ourselves against climate disruptions, and also an alliance for health. Here too, I want to salute INSERM and all the great French research institutes for this cooperation you have engaged in with our African friends.

French research, particularly in the field of health, has come together. It is never easy, and this applies to all professions, to all organizations, and even to political parties. Coming together is not easy. Everyone thinks they have their identity, their uniqueness, their particularity, their personalities. You have succeeded, like others, because you must be an example for others to show that, without losing any originality of your institutes, you could come together: INSERM, CNRS, the Pasteur Institute, CEA, universities, INRA, INRIA, and IRD. All this in an alliance for life and health sciences (AVIESAN) that you preside over, Mr. SYROTA.

Thanks to AVIESAN, our system has become more responsive, more efficient, more readable, and therefore stronger. First internationally. Thanks to AVIESAN, partnerships are simplified with foreign laboratories, with countries in the South. I was just talking about the health crises that can be better contained and fought.

The AVIESAN alliance is also about having a research strategy in France and promoting it. It is the hope of new discoveries and it is also the transfer to health industries. Because one of your missions is to ensure that this research can be useful and that it can also contribute to the vitality of our economy.

Here too, important decisions have been made with the creation of INSERM-Transfert and then INSERM-Transfert Initiatives in 2005, this subsidiary of which you told me, Mr. President, as if to reassure me, that it was making profits. To reassure me, no doubt! And to worry others! How? Profits from research? Why should there be profit in these areas? But that is not the point. It is about ensuring that research can be valued, that your work can be paid at the right price so that industries can engage. There is nothing here that should be suspect; on the contrary, I do not encourage you to replenish the state budget through your subsidiary, but it is also a sign of the effectiveness of your institution.

Biomedical research drives the country's economy. We often ask ourselves this question: what will be the dominant sectors in terms of job creation, wealth creation in the coming years? All the work we have asked of our greatest economists, all our experts, all the great industrialists have always placed the life economy as one of our most essential priorities, as one of our chances to be the best in the world.

If we think about what exists thanks to this activity: 600,000 direct and indirect jobs have already been created, particularly in the biotechnology sectors. There is more than 7.5 billion euros of investment being made in the life economy. The government, following the GALLOIS report, has therefore made health and the life economy one of the top priorities for the industrial recovery of France.

I then asked Anne LAUVERGEON to imagine what disruptive innovations could be, that is to say, those that would change the game for the next 30 years. She identified, with a commission of experts, personalized medicine among the seven disruptive innovations on which our country can aspire to be a world leader tomorrow. So I want to emphasize this: research is not detached from what we have to do for the economy of our country. Without strong research, there is no strong economy. Without public research, there is no dynamic private economy. Research must therefore be a priority for France.

What is a priority? In France, we only have priorities; that is the problem: we add them up. A priority is to say what we will do and what we will not do. Or what we will no longer do. It is to make savings where possible, to better invest where it is essential.

Research is an investment. It is the key to our competitiveness. It is also an invitation for society to mobilize around its research. That is why in the government I formed with Prime Minister Manuel VALLS, I wanted there to be a full ministry of Education, Higher Education, and Research within which there will, of course, be Higher Education and Research that will be particularly and personally identified.

A priority is not simply a ministry; otherwise, there would need to be so many! A priority is also budgetary means. This is where it gets complicated in a context of difficult public finances and where the European Commission makes our task easier but, at the same time, demands from us. This is legitimate given our commitments.

We have to make choices and allocate resources to research for the coming years. I have also made a commitment: public research will be safeguarded because it is essential. Even if we have savings to make elsewhere, we will not make them in this fundamental area for our country.

The government has defined a strategic agenda for research "France/Europe 2020" because we are linked to what is being done in Europe. We are indeed obtaining significant funding from Europe, and we must obtain more. I do not say this because the Commissioner is here, but because we have often talked about it; we have not sufficiently solicited Europe, even though resources exist. In this strategy, the orientations in health matters have been specified. We must focus on cutting-edge sectors in biotechnology: genomics, functional brain imaging, synthetic biology, stem cells.

We must also improve the efficiency of our health policy; this is the role of Marisol TOURAINE in all its components, from prevention to response to epidemics, from the management of chronic diseases to support for aging.

We do not only have budgetary resources; we also have the future investments that have already been mobilized, as 190 projects are funded in the field of health for an amount of 4 billion euros. The second tranche of the future investments program will be released next July. Biomedical research will particularly benefit from the creation of new "Excellence Initiatives," the famous IDEX, as well as new hospital-university departments. A support plan will be launched in favor of systems biology and digital technologies applied to health.

Research must lead to care. Today, the clinical research actions conducted by hospitals and the projects led by research organizations are designed independently of each other. We will need to group, bring together, and coordinate. Starting in 2015, research actions involving hospitals will be linked to the AVIESAN alliance. There will be unique calls for projects, a common financial programming, and a shared evaluation.

The challenge is always openness, the refusal of compartmentalization, the opening of organizations, the opening of disciplines, the opening towards society, the openness that allows for creativity, the openness that is, in fact, the very foundation of science. But it is true that openness requires, as you reminded us, Mr. President, responding to society's questions, being fully involved in the ethical, philosophical, and sometimes political debates that question science.

In our time, there is not just the researcher. Wherever they are and in whatever field they work, they can no longer simply be an expert, a specialist in their laboratory, cut off from the rest of society. They have a role to play. It has always been this way in democracy. The researcher must explain what they do, provide society with the elements it needs to calmly debate its future, especially when it touches on what we call "societal issues," that is to say, simply living together, understanding the world.

When we no longer understand the world, when we are not able or no longer able to live together, then there is this loss of reference, of meaning that leads to expressions of violence, hatred, or rejection of the other. Here too, science has its role to play to reassure, to provide an explanation, to offer the keys to understanding.

This is what you are doing, with INSERM, on the occasion of your fiftieth anniversary: making science loved, discovering it, promoting it, valuing it. This is the purpose of an anniversary: not simply to look at the past, but to question the conditions of its future. This gives me the opportunity to tell you, the research community, that France must always believe in science, in progress in knowledge, in human understanding. There is a very direct link between the great milestones of our history and the advances of science. It is in the pages of the Encyclopedia that the French Revolution was born, but also the greatest scientific constructions. It was the French Revolution that then unleashed energies for other stages of human destiny.

Under the Republic, there has always been this idea that human progress and scientific progress go hand in hand. Every time education advanced, every time research itself led to discoveries that brought us honor, the entire Republic felt strengthened, glorified, celebrated. That is why the Panthéon has welcomed great scientists, because it was once again a way for the Republic to say that it had confidence in science.

The Republic has always recognized its researchers. When it has not done so, it has committed faults because research is about advancing the human spirit everywhere in the world in its best form. Those who contest science do not simply contest a research or insist on mentioning its risks; they want to fundamentally question the very idea of progress and democracy.

INSERM is France's asset because thanks to you, France is a great scientific nation and a great medical nation. I mentioned the meeting yesterday between Europe and Africa. Wherever I go, whether the country is an advanced country or a poor country, everywhere, every time, French science is regarded. You said yourself that you were second in Europe; that's already quite good! We have ambitions when we are second. We can always think about being first. I often say this. And when we are first, we must remain first.

But what I want to salute here is what France has of the most exhilarating, what it has achieved with the greatest possible pride, it is science, it is research. And you contribute to that. INSERM is the hope of France because France trusts its research to meet the great challenges of health for the next 50 years.

Finally, Mr. President, Ladies and Gentlemen, INSERM is the pride of France because what you do, you do not do for yourselves, you do not do it just for your country, you do it for humanity. And that is how you resemble France.